Application Effect of Dexmedetomidine and Dezocine in Patients Undergoing Lung Cancer Surgery under General Anesthesia and Analysis of Their Roles in Recovery Time and Cognitive Function

Ding, Jie; Zhu, Ming; Lv, Haipeng; Zhang, Jun; Chen, Wei

doi:10.1155/2022/9889534

Cited by 8 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the heterogeneity of the indicator was more than 50%, sensitivity analysis was carried out by excluding the included studies one by one. The analysis results showed that Ding et al ( 17 ) may be the source of heterogeneity, as shown in Figure 5 .…”

Section: Resultsmentioning

confidence: 94%

“…After reviewing the titles and abstracts, 20 were then retained. According to a full-text reading, 11 ( 14 , 17 - 26 ) RCTs were finally included. The literature screening process is illustrated in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…A total of 5 ( 17 , 19 , 22 , 24 , 25 ) studies mentioned TNF-α as an index, involving 592 cases in total. Heterogeneity testing indicated (I 2 =97.3%, P=0.000), so data were consolidated and analyzed using the random effects model.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 4 ( 17 , 23 , 24 , 26 ) studies mentioned the FEV1 index, involving 420 patients in total. Heterogeneity testing indicated (I 2 =88.0%, P=0.000), so the random-effects model was employed for data analysis.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Xu¹,

Zhou²,

Maloney³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Surgical resection is the most effective treatment for lung cancer, but it can also lead to adverse stress reactions in the body. The minimization of lung function damage caused by one-lung ventilation and inflammatory reactions caused by surgery are new challenges faced by the field of anesthesiology. Dexmedetomidine (Dex) has been found to be effective in improving perioperative lung function. In this study, we aimed to conduct a systematic review and meta-analysis to examine the effect of Dex on inflammation and pulmonary function after thoracoscopic surgery for lung cancer. Methods A computer-based search was performed to retrieve controlled trials (CTs) about the effects of Dex on inflammation and lung function after thoracoscopic surgery for lung cancer from the databases of PubMed, Embase, Cochrane Library, and Web of Science. The time period for retrieval was set from inception to 1 August 2022. The articles were strictly screened according to the inclusion and exclusion criteria, and data analysis was conducted using the software Stata 15.0. Results A total of 11 CTs were included, involving 1,026 patients overall, with 512 assigned to the Dex group and 514 to the control group. The meta-analysis showed that after Dex treatment, the inflammatory factors of patients with lung cancer who underwent radical resection were all decreased: interleukin-6 (IL-6) [standardized mean difference (SMD) =−2.09; 95% confidence interval (CI): −3.03, −1.14; P=0.003], interleukin-8 (IL-8) (SMD =−1.12; 95% CI: −1.54, −0.71; P=0.001), and tumor necrosis factor-α (TNF-α) (SMD =−2.04; 95% CI: −3.24, 0.84; P=0.001). The pulmonary function of the patients was also improved: forced expiratory volume in the first second (FEV1) (SMD =0.50; 95% CI: 0.24, 0.76; P=0.003), and partial pressure of oxygen (PaO 2 ) (SMD =1.00; 95% CI: 0.40, 1.59; P=0.001). However, there was no significant difference between the two groups regarding adverse reactions [relative risk (RR) =0.68; 95% CI: 0.41, 1.14; P=0.27]. Conclusions In summary, the use of Dex in lung cancer patients after radical surgery can reduce serum inflammatory factors, and this may play an important role in postoperative inflammatory reaction and improving lung function.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Xu¹,

Zhou²,

Maloney³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…In individuals with tumors, dexmedetomidine can decrease the body's stress reaction and alleviate the suppression of cellular immunological function. In addition, dexmedetomidine has good sedative and hypnotic effects, which can effectively relieve pain, inhibit sympathetic activity and improve cardiovascular stability (10,11). However, whether the combination of the two can improve the postoperative T lymphocytes, NK cells and cognitive function of individuals with gastrointestinal cancer needs further verification.…”

Section: Introductionmentioning

confidence: 99%

Effects of dexmedetomidine combined with dezocine on T lymphocytes, NK cells and cognitive function in elderly patients with gastrointestinal cancer after radical surgery

Zijian Ai

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Trial watch: dexmedetomidine in cancer therapy

Carnet Le Provost,

Kepp,

Kroemer

et al. 2024

OncoImmunology

View full text Add to dashboard Cite

Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery, thus harboring therapeutic benefits for oncological procedures. Recently, the molecular mechanisms of DEX-mediated anticancer effects have been partially deciphered. Together with additional preclinical data, these mechanistic insights support the hypothesis that DEX-induced therapeutic benefits are mediated via the stimulation of adaptive anti-tumor immune responses. Similarly, published clinical trials including ancillary studies described an immunostimulatory role of DEX during the perioperative period of cancer surgery. The impact of DEX on long-term patient survival remains elusive. Nevertheless, DEX-mediated immunostimulation offers an interesting therapeutic option for onco-anesthesia. Our present review comprehensively summarizes data from preclinical and clinical studies as well as from ongoing trials with a distinct focus on the role of DEX in overcoming (tumor microenvironment (TME)-imposed) cancer therapy resistance. The objective of this update is to guide clinicians in their choice toward immunostimulatory onco-anesthetic agents that have the capacity to improve disease outcome.

show abstract

Application Effect of Dexmedetomidine and Dezocine in Patients Undergoing Lung Cancer Surgery under General Anesthesia and Analysis of Their Roles in Recovery Time and Cognitive Function

Cited by 8 publications

References 22 publications

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Effects of dexmedetomidine on inflammation and pulmonary function after thoracoscopic surgery for lung cancer: a systematic review and meta-analysis

Effects of dexmedetomidine combined with dezocine on T lymphocytes, NK cells and cognitive function in elderly patients with gastrointestinal cancer after radical surgery

Trial watch: dexmedetomidine in cancer therapy

Contact Info

Product

Resources

About